Department of Radiotherapy, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
Redox Rep. 2024 Dec;29(1):2433396. doi: 10.1080/13510002.2024.2433396. Epub 2024 Nov 28.
OBJECTIVE: Intracellular redox homeostasis is crucial for a series of physiological processes. Reactive oxygen species (ROS) play important roles in redox processes. ROS can maintain cell reproduction and survival at moderate levels while promoting the initiation and progression of tumors at high levels. METHODS: Based on a comprehensive analysis of ROS-related gene expression profiles, we established a gene signature associated with ROS to explore its influence on prognosis and immune microenvironment in gliomas. RESULTS: The ROS-related gene expression profile dichotomized patients into two groups with different clinicopathological features and prognoses. A 19-gene ROS-related signature was used to robustly predict prognosis in both training and validation datasets. Functional analysis indicated an association between ROS levels and the immune microenvironment. The expression of immune checkpoints and M2-type markers was upregulated in the high-risk group, which suggested the immunosuppressive function of ROS. CONCLUSION: ROS-related signature is an independent prognostic factor in gliomas and could potentially exert immunosuppressive effects on the tumor microenvironment.
目的:细胞内氧化还原稳态对一系列生理过程至关重要。活性氧(ROS)在氧化还原过程中发挥重要作用。ROS 可以在中等水平维持细胞繁殖和存活,而在高水平时促进肿瘤的发生和发展。
方法:基于对 ROS 相关基因表达谱的综合分析,我们建立了一个与 ROS 相关的基因特征,以探讨其对脑胶质瘤预后和免疫微环境的影响。
结果:ROS 相关基因表达谱将患者分为两组,具有不同的临床病理特征和预后。使用 19 个 ROS 相关基因的特征可以在训练和验证数据集中稳健地预测预后。功能分析表明 ROS 水平与免疫微环境之间存在关联。在高危组中,免疫检查点和 M2 型标志物的表达上调,提示 ROS 具有免疫抑制功能。
结论:ROS 相关特征是脑胶质瘤的一个独立预后因素,可能对肿瘤微环境产生免疫抑制作用。
Clin Transl Oncol. 2025-5
Biochim Biophys Acta Rev Cancer. 2024-9
Nat Rev Drug Discov. 2024-8
Cell Biosci. 2024-4-17
Front Immunol. 2023
J Clin Invest. 2023-11-16
Cell Death Dis. 2023-10-13
Pharmaceuticals (Basel). 2023-1-1